Gilead, Cipla Ink Deal To End HIV Drug Buyers' Antitrust Suit

By Gina Kim

Gilead Sciences Inc. and generics maker Cipla told a California federal judge Friday they've reached a settlement ending a proposed class action filed by a public employees' health insurance fund over an alleged anti-competitive patent deal to delay the launch of a generic version of the HIV drug Truvada.

 1 document attached | Read full article » | Save to favorites »